HELLO! speaks to leading experts about the simple mistakes that can hold back results of weight loss injections or lead to ...
Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...
At World Sleep 2025, a discussion group examined the emerging role of GLP-1 receptor agonists in obstructive sleep apnea (OSA ...
Recent advancements in medical therapy for heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection ...
One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...
Working together as a team to better communicate between physicians and nurses as well as the complete caregiving team will ...
Two experts discussed innovative trial designs in rare disease research, common challenges and the potential of AI to enhance ...
The DeMenna family has helped shape Arizona law for generations as one of the Arizona Capitol’s most recognizable and respected public affairs firms.
Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...
Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...
A cannabis extract appears to provide sustained relief from chronic low back pain without signs of addiction or withdrawal, ...
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback